Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2141.1987.tb04163.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multiple autoimmune disorders refractory to glucocorticoids after allogeneic hematopoietic stem cell transplantation: a case report and review of the literature.
Front Immunol
May 2024
Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Article Synopsis
- A 50-year-old man diagnosed with myelodysplastic syndrome underwent a successful stem cell transplant in 2019 but later developed multiple autoimmune disorders in 2021, known as multiple autoimmune syndrome (MAS).
- Despite treatment with glucocorticoids and other medications, he did not fully recover from MAS.
- A four-week course of rituximab significantly improved his condition, emphasizing the need for alternative treatments in patients with treatment-resistant post-transplant autoimmune diseases.
Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
Clin Lymphoma Myeloma Leuk
March 2024
AbbVie, North Chicago, IL.
Article Synopsis
- The study aimed to evaluate the effectiveness of hypomethylating agents, azacitidine (AZA) and decitabine (DEC), for treating patients with refractory anemia with excess blasts (RAEB), a serious type of bone marrow disorder, using real-world data from the SEER-Medicare database.
- Out of 973 patients aged 66 and older, those treated with AZA had a median overall survival of 13.9 months and a 38% rate of progression to acute myeloid leukemia (AML), with similar outcomes for DEC, indicating no significant differences between the two treatments.
- The results showed that the median overall survival was shorter in real-world settings compared to
Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy.
Hematol Oncol
January 2024
Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Article Synopsis
- * A study compared outcomes from 999 adult MDS patients who received either matched sibling donor (MSD) HCT or single-unit unrelated cord blood (UCB) HCT, finding no significant differences in overall survival or disease-free survival between the two groups.
- * UCB recipients experienced lower neutrophil and platelet recovery but had a reduced incidence of chronic graft-versus-host disease (GVHD) compared to MSD recipients, highlighting different recovery profiles despite similar survival outcomes.
Case Series Using Salvage Haplo-Identical Stem Cells for Secondary Transplantation.
Medicina (Kaunas)
June 2023
Fundeni Clinical Institute, 022328 Bucharest, Romania.
In order to expand the donor pool and accessibility of the transplant procedure, it was necessary to introduce haplo-identical stem cell transplants in the Fundeni Clinical Institute from 2015. Even if the Romanian population is an ethnically compact white population, many of the patients referred for bone marrow transplant lack a suitable donor. Hematopoietic stem cell transplant from a haplo-identical donor is an alternative option for those patients without an HLA (Human Leucocyte Antigen)-matched donor (sibling or matched unrelated).
View Article and Find Full Text PDFThe effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol
March 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address:
Background: Relapse remains high in patients with myelodysplastic syndrome-refractory anaemia with excess blasts (RAEB) or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate whether granulocyte-colony stimulating factor (G-CSF) and decitabine plus busulfan-cyclophosphamide conditioning reduced relapse compared with busulfan-cyclophosphamide in this population.
Methods: We did an open-label, randomised, phase 3 trial at six hospitals in China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!